« Back
Home /
cetuximab

cetuximab

Item no.	V4372-25mg
Manufacturer	InvivoChem LLC
CASRN	205923-56-4
Amount	25 mg
Quantity options	100 mg 10 mg 1 mg 250 mg 50 mg 5 mg
Category	Reagents & Chemicals Molecules
Type	Biochemicals
Specific against	other
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Available
Description	InvivoChem Cat #:V4372CAS #:N/A; Purity >=98% Description: Cetuximab (C225; C 225; C-225)is a potent and specific chimeric monoclonal antibody that inhibits epidermal growth factor receptor (EGFR) with a Kd of 0.201 nM for soluble EGFR by SPR. Cetuximab has potent antitumor activity and is used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is distributed under the trade name Erbitux in the U.S. and Canada by the drug company Eli Lilly and Co. and outside those countries by the drug company Merck KGaA. In Japan, Merck KGaA, Bristol-Myers Squibb and Eli Lilly have a co-distribution. References: Clin Cancer Res. 1995 Nov; 1(11):1311-8.
In vitro	Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for soluble EGFR by SPR. Cetuximab also exhibits a Kd of 0.147 nM for EGFR in fixed A431 cells by ELISA. Cetuximab (C225; 30 nM) time-dependently inhibits the proliferation of SCC-1, SCC-11B, SCC-38, and SCC-13Y cells after treatment for 8 d. Cetuximab (30 nM) causes G0/G1 arrest, induces apoptosis, and reduces Rb, p27KIP1, Bcl-2, and Bax expression in SCC-13Y cells. Cetuximab (30 nM) also enhances radiosensitivity and increases radiation-induced apoptosis in SCC-13Y cells.
In Vivo	Cetuximab (1?mg/injection) has effect on the tumour volume but the effect is more pronounced on UT-SCC-14 xenografts. In UT-SCC-14 xenografts, Cetuximab treatment significantly reduces the expression of EGFR, pEGFR and Ki67. The MCT1 and GLUT1 expression is significantly decreased in the Cetuximab-treated groups of both cell lines but differences are more pronounced in UT-SCC-14 xenografts.
Protocol
References	Clin Cancer Res. 1995 Nov; 1(11):1311-8.; Cancer Res. 1999 Apr 15; 59(8):1935-40.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 25 mg

available

Delivery expected until 9/4/2025

Express Delivery: Save 15 days

Compare

Add to wishlist

Get an offer